Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 142, Issue 6, Pages 1710-1718Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2018.10.015
Keywords
Regulatory T cell; cell therapy; transplant; autoimmune disease; clinical trials; Good Medical Practice manufacturing
Categories
Funding
- Leukemia and Lymphoma Society [5459-17]
- Swiss National Science Foundation [P300PB_174500]
- Swiss National Science Foundation (SNF) [P300PB_174500] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Forkhead box P3-expressing regulatory T (Treg) cells are essential for self-tolerance, with an emerging role in tissue repair and regeneration. Their ability to traffic to tissue and perform complex therapeutic tasks in response to the tissue microenvironment make them an attractive candidate for drug development. Early experiences of Treg cell therapy in patients with graft-versus-host disease, type 1 diabetes, and organ transplantation have shown that it is feasible, safe, and potentially efficacious in some settings. Many ongoing trials in patients with a wide variety of diseases will further enhance our knowledge about the optimal approaches for Treg cell manufacturing and dosing. We review the current preclinical rationale supporting Treg cell therapy in a variety of disease settings ranging from tissue transplantation, autoimmune diseases, and non-immunemediated inflammatory settings. We point out challenges in development of Treg cell therapy and speculate how synthetic biology can be used to enhance the feasibility and efficacy of Treg cell therapy for autoimmune and autoinflammatory diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available